{name}
{subtitle}
A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread
city
~64 mi. (Tallaght, Ireland, +84 more cities)
facility
Tallaght University Hospital
drug
nivolumab, +1 more drug
drug type
immunotherapy, +1 more type
Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
city
~72 mi. (Dublin, Ireland, +247 more cities)
facility
St. James'S Hospital
biomarker
ER Positive, +1 more biomarker
drug
anthracycline, +4 more drugs
drug type
chemotherapy, +2 more types
Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
city
~72 mi. (Dublin, Ireland, +137 more cities)
facility
St. James s Hospital ( Site 1601)
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
city
~72 mi. (Dublin, Ireland, +105 more cities)
facility
Mater Misericordiae University Hospital ( Site 1654)
biomarker
ATM Loss, +62 more biomarkers
condition
Breast Carcinoma, +2 more conditions